Product Description
Lapatinib is a small molecule inhibitor of several tyrosine kinase receptors involved in tumor cell growth that is used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lapatinib)
Mechanisms of Action: ERBB2 Inhibitor,EGFR Inhibitor,TK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Korea, Turkey, United States, Unknown Location
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Breast Cancer|Sarcoma
Phase 2: Glioblastoma|Intestinal Cancer|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT01591577 | P2 |
Completed |
Glioblastoma |
2024-05-07 |
|
| MULTISARC | P3 |
Active, not recruiting |
Sarcoma |
2023-12-31 |
|
| ROME | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Breast Cancer|Intestinal Cancer |
2023-09-07 |
|
| CTR20170251 | P3 |
Active, not recruiting |
Breast Cancer |
2018-10-17 |